4 completed, 4 recruiting, 3 terminated, 2 active not recruiting. 10 Phase 1, 3 Phase 2, 2 Phase 4, 1 Not applicable.
Follow Maximum Tolerated Dose: new trials by email Literature Review of Maximum Tolerated Dose trials Research Report on Maximum Tolerated Dose
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer ITI-5000 mRNA Vaccine, Pembrolizumab, Olaparib - Triple Negative Breast Cancer (TNBC) | Phase 1 | Recruiting | Immunomic Therapeutics, Inc. | 60 | 2026-07-14 | 2026-09-10 |
| Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma BCMA-TGFβ CAR-T cells (0.50 x 10^6 cells/kg), BCMA-TGFβ CAR-T cells (0.75 x10^6 cells/kg), BCMA-TGFβ CAR-T cells (1 x 10^6 cells/kg) - Multiple Myeloma | Phase 1 | Recruiting | Medical College of Wisconsin | 30 | 2026-05-15 | 2026-08-10 |
| Investigating Idetrexed and Olaparib in Patients With Ovarian Cancer Dose Level 2 (starting dose), Dose Level 1, Dose Level -1 - High Grade Serous Ovarian Cancer | Phase 1 | Recruiting | Institute of Cancer Research, United Kingdom | 33 | 2025-08-01 | 2025-08-13 |
| Effectiveness of Nontraditional Hydroxyurea Algorithms: Novel and Clinical Evaluations (ENHANCE) PK-optimized oral hydroxyurea at MTD until 15 years of age. - Sickle Cell Anemia (HbSS), Sickle-β0-thalassemia (HbSβ0) | Phase 4 | Recruiting | Children's Hospital Medical Center, Cincinnati | 50 | 2024-12-19 | 2025-09-16 |
| COPILOT-HF: Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure SGLT2i, beta blocker, ARNI, MRA, MTD, Education-First - Heart Failure | Phase 4 | Completed | Brigham and Women's Hospital | 503 | 2023-05-05 | 2026-02-06 |
| D,L-MEthadone and mFOLFOX6 in Treatment of Advanced Colorectal Cancer Maximum tolerated dose, MTD: D,L-methadone hydrochloride (Methasan® 10 mg/ml) - Chemo-refractory Colorectal Carcinoma | Phase 1 / Phase 2 | Active not recruiting | AIO-Studien-gGmbH | 11 | 2022-02-17 | 2025-10-03 |
| Anti-SARS Cov-2 T Cell Infusions for COVID 19 Dose Finding Phase (MTD), Partially HLA-matched SARS-CoVSTs, Routine care (no SARS-CoVSTs) - SARS-CoV 2, Viral Infection | Phase 1 | Terminated | Baylor College of Medicine | 4 | 2020-11-04 | 2022-12-19 |
| Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC 350 mg leronlimab, 525 mg leronlimab, 700 mg leronlimab - Triple Negative Breast Neoplasms | Phase 1 / Phase 2 | Terminated | CytoDyn, Inc. | 10 | 2019-04-22 | 2025-09-09 |
| PRE-ProstAtectomy MRI-GuidEd Stereotactic Body RadioTherapy for High-Risk Prostate Cancer Trial (PREPARE SBRT) 5 Gy x 5 fractions, 6 Gy x 5 fractions, 6.5 Gy x 5 fractions - Prostate Cancer | Not applicable | Active not recruiting | Weill Medical College of Cornell University | 16 | 2018-10-24 | 2026-03-18 |
| A Study of PVP001, PVP002, and PVP003 in Healthy Adults and PVP001 and PVP002 in Adults With Celiac Disease PvP001 placebo, PvP001 100 mg, PvP001 300 mg - Digestive System Disease | Phase 1 | Completed | Millennium Pharmaceuticals, Inc. | 139 | 2018-06-19 | 2023-04-04 |
| A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination With M9241(NHS-IL12) (JAVELIN IL-12) Avelumab, M9241, Avelumab (Once weekly) - Advanced Solid Tumors | Phase 1 | Terminated | EMD Serono Research & Development Institute, Inc. | 52 | 2017-01-31 | 2024-09-20 |
| Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma MLN9708, Dexamethasone, Bendamustine (multiple dose levels) - Multiple Myeloma | Phase 1 / Phase 2 | Completed | Parameswaran Hari | 38 | 2015-10-09 | 2020-10-22 |
| A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations Dose escalation followed by treatment with MTD - Carcinoma, Non-Small-Cell Lung | Phase 1 | Completed | Boehringer Ingelheim | 35 | 2012-07-01 | 2017-01-31 |
Multiple Myeloma (2) · Triple Negative Breast Neoplasms (2) · Anemia, Sickle Cell (1) · COVID-19 (1) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Digestive System Diseases (1) · Heart Failure (1) · Ovarian Neoplasms (1) · Prostatic Neoplasms (1) · Virus Diseases (1)
AIO-Studien-gGmbH (1) · Baylor College of Medicine (1) · Boehringer Ingelheim (1) · Brigham and Women's Hospital (1) · Children's Hospital Medical Center, Cincinnati (1) · CytoDyn, Inc. (1) · EMD Serono Research & Development Institute, Inc. (1) · Immunomic Therapeutics, Inc. (1) · Institute of Cancer Research, United Kingdom (1) · Medical College of Wisconsin (1) · Millennium Pharmaceuticals, Inc. (1) · Parameswaran Hari (1) · Weill Medical College of Cornell University (1)
United States (11) · Belgium (1) · France (1) · Germany (1) · Hungary (1) · Italy (1) · Netherlands (1) · Spain (1) · United Kingdom (1)
Binod Dhakal, MD (1) · Charles T. Quinn, Professor of Pediatrics, M.D., M.S. (1) · Jacob Lalezari, MD (1) · Parameswaran Hari, MD, MRCP, MS (1) · Premal Lulla (1) · Professor Udai Banerji (1) · Silvia C. Formenti, M.D. (1) · Thomas Seufferlein, Prof.Dr.med. (1)
PMID 33741317, PMID 36373249, PMID 37236636, PMID 41652651
2017 (1)